Inventor · disambiguated record
Matthias Eder
Also filed as: EDER MATTHIAS
14 granted patents·12 pending applications·76 citations·filing 2006–2024
91Inventor score
Files withDEUTSCHES KREBSFORSCH17DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS3NOVARTIS AG2MAX PLANCK GESELLSCHAFT1MEDIZINISCHE HOCHSCHULE HANNOVER1
Top patents by PatentIndex Score
26 records- 0196US11951190B2Use of labeled inhibitors of prostate specific membrane antigen (PSMA), as agents for the treatment of prostate cancerDEUTSCHES KREBSFORSCH·Filed 2021·Granted Apr 9, 2024·4 cites·62 claims
- 0296US11931430B2Labeled inhibitors of prostate specific membrane antigen (PSMA) as agents for the treatment of prostate cancerDEUTSCHES KREBSFORSCH·Filed 2020·Granted Mar 19, 2024·5 cites·15 claims
- 0396US11045564B2Labeled inhibitors of prostate specific membrane antigen (PSMA) as agents for the treatment of prostate cancerDEUTSCHES KREBSFORSCH·Filed 2019·Granted Jun 29, 2021·10 cites·15 claims
- 0496US10398791B2Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancerDEUTSCHES KREBSFORSCH·Filed 2018·Granted Sep 3, 2019·22 cites·30 claims
- 0594US10471160B2Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancerDEUTSCHES KREBSFORSCH·Filed 2018·Granted Nov 12, 2019·16 cites·28 claims
- 0693US10815200B218F—tagged inhibitors of prostate specific membrane antigen (PSMA) and their use as imaging agents for prostate cancerDEUTSCHES KREBSFORSCH·Filed 2018·Granted Oct 27, 2020·8 cites·8 claims
- 0791US10016519B218F-tagged inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancerDEUTSCHES KREBSFORSCH·Filed 2017·Granted Jul 10, 2018·8 cites·18 claims
- 0890US2024382631A1Use of labeled inhibitors of prostate specific membrane antigen (psma), as agents for the treatment of prostate cancerNOVARTIS AG·Filed 2024·Application pending·0 cites
- 0989US2024350680A1Labeled inhibitors of prostate specific membrane antigen (psma) as agents for the treatment of prostate cancerNOVARTIS AG·Filed 2024·Application pending·0 cites
- 1083US12054458B218F-tagged inhibitors of prostate specific membrane antigen (PSMA) and their use as imaging agents for prostate cancerDEUTSCHES KREBSFORSCH·Filed 2023·Granted Aug 6, 2024·0 cites·12 claims
- 1181US11020493B2Double-labeled probe for molecular imaging and use thereofDEUTSCHES KREBSFORSCH·Filed 2019·Granted Jun 1, 2021·1 cites·7 claims
- 1279US11452786B2Double-labeled probe for molecular imaging and use thereofDEUTSCHES KREBSFORSCH·Filed 2018·Granted Sep 27, 2022·1 cites·66 claims
- 1371US10406246B2Double-labeled probe for molecular imaging and use thereofDEUTSCHES KREBSFORSCH·Filed 2014·Granted Sep 10, 2019·1 cites·11 claims
- 1471US2019336622A1Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancerDEUTSCHES KREBSFORSCH·Filed 2019·Application pending·0 cites
- 1568US12156920B2Double-labeled probe for molecular imaging and use thereofDEUTSCHES KREBSFORSCH·Filed 2022·Granted Dec 3, 2024·0 cites·22 claims
- 1668US2021053922A118f - tagged inhibitors of prostate specific membrane antigen (psma) and their use as imaging agents for prostate cancerDEUTSCHES KREBSFORSCH·Filed 2020·Application pending·0 cites
- 1762US2016228587A1Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancerDEUTSCHES KREBSFORSCH·Filed 2016·Application pending·0 cites
- 1859US2025303005A1Prostate specific membrane antigen (psma) ligands with improved renal clearanceDEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS·Filed 2023·Application pending·0 cites
- 1959US2025312496A1Prostate specific membrane antigen (psma) ligandsDEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS·Filed 2023·Application pending·0 cites
- 2058US2025360236A1Prostate specific membrane antigen (psma) ligandsDEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS·Filed 2023·Application pending·0 cites
- 2150US2022118121A1Prostate specific membrane antigen (psma) ligands with improved tissue specificityUNIV HEIDELBERG RUPRECHT KARLS·Filed 2020·Application pending·0 cites
- 2248US2022324898A1Prostate specific membrane antigen (psma) ligands comprising an amylase cleavable linkerDEUTSCHES KREBSFORSCH·Filed 2020·Application pending·0 cites
- 2345US11638765B2Double-labeled probe for molecular imaging and use thereofDEUTSCHES KREBSFORSCH·Filed 2018·Granted May 2, 2023·0 cites·41 claims
- 2445US11333660B2Analytical process for predicting the therapeutic effect of BH3 mimeticsMEDIZINISCHE HOCHSCHULE HANNOVER·Filed 2018·Granted May 17, 2022·0 cites·16 claims
- 2545US2023201383A1Psma targeting urea-based ligands for prostate cancer radiotherapy and imagingRIGSHOSPITALET·Filed 2021·Application pending·0 cites
- 2642US2008234597A1Monitoring Neuronal SignalsMAX PLANCK GESELLSCHAFT·Filed 2006·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Matthias Eder files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →